Accordingly, Fowler and colleagues reported that PTH intermittent treatment in Ts65Dn mice significantly increased bone mass and volume suggesting that anabolic treatments, as intermittent-PTH and anti-sclerostin antibodies (127), may be effective in improving BMD in subjects with DS (136). Here, PTH is linked to Dravet syndrome.